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Gla-rich protein is a novel 
vitamin K-dependent protein 
present in serum that accumulates 
at sites of pathological calcifications
Viegas et al., Am J Pathol 2009; 175: 2288–2298; doi:10.2353/
ajpath.2009.090474
Extracellular matrix calcification is a naturally occurring process 
that must be actively inhibited outside bone. The process starts 
to appear as soon as inhibitors are removed from the matrix. The 
regulation of this complex process involves key genes that act 
as calcification inhibitors, such as those for matrix Gla protein 
(MGP), osteocalcin (BGP), bone sialoprotein (BSP), osteoprote-
gerin (Opg), and fetuin. Viegas et al. identified in sturgeon a new 
vitamin K-dependent protein, Gla-rich protein (GRP), that con-
tains the highest ratio of the number of Gla residues to the size 
of the mature protein identified to date. They show that GRP is 
a circulating protein also expressed and accumulated in soft tis-
sues of rats and humans, including the skin and vascular system, 
in which, when affected by pathological calcifications, GRP accu-
mulates at high levels at sites of mineral deposition (Figure), indi-
cating an association with calcification processes. Research shows 
that inhibition of extrahepatic carboxylation by warfarin induces 
vascular media calcification in rats, consistent with the finding in 
humans associating high vitamin K intake with low aorta calcifi-
cation and beneficial effects on the elastic properties of the vessel 
wall. Moreover, a high vitamin K intake can reverse preexisting 
arterial calcification in rats. As vitamin K is an essential cofactor in 
the γ-carboxylation reaction catalyzed by the γ-glutamyl carboxy-
lase, and warfarin prevents γ-carboxylation, interfering with the 
vitamin K-recycling VKOR enzyme, some of the effects observed 
with warfarin and/or vitamin K administration are due, conceiv-
ably, to impairment and/or improvement of GRP function. 
In conclusion, the new type of vitamin K-dependent protein 
described seems to play an important role in the process of 
vascular calcifications in humans, which leaves one looking 
forward to the next step.
Marc De Broe
Vasopressin regulation  
of the epithelial Na+ channel
Bugaj et al., Am J Physiol Renal Physiol 2009; 297: F1411–F1418; doi:10.1152/
ajprenal.00371.2009
While renal water handling is the most apparent role of vasopressin 
in the kidney, it has long been known that this hormone also regu-
lates renal sodium reabsorption, particularly in the thick ascending 
limb and collecting duct. Both the activity and the abundance of 
some of the sodium transport proteins expressed in these segments, 
such as the bumetanide-sensitive Na-K-2Cl cotransporter and the 
epithelial sodium channel (ENaC), were found to be increased by 
vasopressin. Interestingly, in experiments done in collecting ducts, 
sodium transport in response to vasopressin was nearly undetect-
able without pretreatment of animals with mineralocorticoids, sug-
gesting a complex interplay between aldosterone and vasopressin 
in regulating sodium transport in this part of the nephron. Abun-
dant evidence suggests that vasopressin increases ENaC activity 
in the principal cells of the collecting duct, but this has not been 
tested directly. In a recent study, Bugaj et al. used the patch-clamp 
technique to examine this question. They found that vasopressin 
increased ENaC activity by quickly (within 2–3 minutes) increasing 
the open probability (Po) of the channel. This action was dependent 
on adenylyl cyclase and protein kinase A. Water restriction and pre-
treatment of isolated collecting ducts with vasopressin, in addition 
to increasing Po, also increased the number of active ENaCs in the 
apical membrane. Interestingly, combined water and salt restriction 
separately and jointly revealed an important effect of vasopressin: 
conservation of water and sodium each independently increased 
ENaC activity and jointly had a synergistic effect on channel activity 
(Figure). These results highlight the important role of vasopressin 
in ENaC regulation and further support the hypothesis that the 
combined actions of vasopressin and aldosterone are required to 
achieve maximally activated ENaC.
Juan Oliver
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The need to conserve water and the need to conserve sodium work in 
synergy to set ENaC activity in the collecting duct. Left: Open probability 
(Po) of the epithelial sodium channel. Right: Number of channels in 
principal cells from collecting ducts isolated from animals fed a high-Na+ 
or nominally Na+-free diet with free and restricted access to water.
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Gla-rich protein is highly accumulated in the human vascular system at 
sites of pathological calcification of human arteries from both chronic 
kidney disease patients (a–d) and postmortem samples (e–h).
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Serum amyloid P inhibits fibrosis  
through FcγR-dependent monocyte– 
macrophage regulation in vivo
Castaño et al., Sci Transl Med 2009; 1: 5ra13; doi:10.1126/
scitranslmed.3000111
Progression of chronic renal diseases, irrespective of the initial 
etiology, remains the major problem in nephrology. All forms 
of progressive fibrosis are associated with a sterile inflammatory 
process, and increasing evidence points to innate activation of 
inflammatory cells in driving chronic organ fibrosis. Castaño et al. 
report on a new approach evaluating serum amyloid P (SAP), also 
known as pentraxin-2. C-reactive protein (CRP), the other mem-
ber of the pentraxin family, is a well-known marker of inflamma-
tion. SAP is produced in the liver and circulates as a highly stable 
135-kDa pentamer composed of five noncovalently linked 27-kDa 
protomers associated into a ring-like structure. Each protomer can 
bind both pathogen-associated molecular patterns (PAMPs; for 
example, lipopolysaccharide and zymosan) and danger- or dam-
age-associated molecular patterns (DAMPs; for example, DNA, 
chromatin, and phosphorylethanolamine) presented on the mem-
branes of apoptotic cells. SAP binding to such ligands promotes 
subsequent Fcγ receptor (FcγR)-dependent phagocytosis, linking 
cell injury to activation of innate immunity. These unique binding 
activities of SAP suggest that it may localize specifically to sites of 
injury and aid in the removal of damaged tissue and pathogenic 
organisms. Castaño et al. show that fibrosis progression in the 
mouse kidney is significantly inhibited by therapeutic administra-
tion of human SAP (Figure). Human-SAP-mediated inhibition 
of mouse kidney fibrosis correlated with specific binding of SAP 
to cell debris and with subsequent suppression of inflammatory 
monocytes and kidney macrophages in vitro and in vivo and was 
dependent on regulated binding to activating FcγRs and inter-
leukin-10 expression.
These novel studies point toward previously unidentified roles 
for FcγRs in sterile inflammation and toward SAP as a potential 
immune-modulatory and antifibrotic therapy through local 
generation of interleukin-10, modulating the inflammatory, 
profibrotic response to a ‘healing’ one. Thus, the two pentraxins, 
CRP and SAP, would serve as anti-inflammatory mediators, with 
CRP being important mostly in acute and SAP mostly in chronic 
inflammation and the associated fibrosis.
Detlef Schlöndorff
Abacavir–lamivudine versus 
tenofovir–emtricitabine  
for initial HIV-1 therapy
Sax et al., N Engl J Med 2009; 361: 2230–2240
Nephrologists must frequently assist in the care of patients with 
renal toxicities related to antiretroviral medications. Therefore, 
knowledge of trials such as the one by Sax et al. in persons with 
HIV is tremendously important. This study randomized 1858 
antiretroviral-naive patients to one of four once-daily regimens. 
The primary end point was time to virologic failure (a rise of HIV 
viral load after initial suppression). An independent data and 
safety monitoring board found this interim analysis sufficient 
to warrant stopping further study of abacavir–lamivudine 
among participants with a screening HIV RNA level greater 
than 100,000 copies per milliliter. Half of the subjects were 
randomized to abacavir–lamivudine and the other half to 
tenofovir–emtricitabine. The abacavir–lamivudine group had a 
shorter time to virologic failure than the tenofovir–emtricitabine 
group. The probability of continued virologic suppression beyond 
48 weeks was 0.84 in the abacavir–lamivudine group and 0.93 
in the tenofovir–emtricitabine group. With respect to adverse 
events, 130 subjects who received abacavir–lamivudine and 78 
who received tenofovir–emtricitabine had at least one grade 3 or 
4 toxicity. Further, the time to a safety end point was significantly 
shorter with abacavir–lamivudine than with tenofovir–emtric-
itabine. Particularly notable was the greater rise of fasting lipid 
levels in patients receiving abacavir–lamivudine (median change 
in total cholesterol level: 34 versus 26 mg/dl). There were no dif-
ferences in suspected drug-related hypersensitivity reactions. 
Interestingly, there were two cases of renal failure in each group. 
Further, at week 48, the median change in creatinine clearance 
from baseline in patients assigned to nucleoside reverse-tran-
scriptase inhibitors was 4 ml/min (interquartile range (IQR) –7 
to 16) in the abacavir–lamivudine group and 2 ml/min (IQR –11 
to 16) in the tenofovir–emtricitabine group.
Case reports clearly demonstrate a risk of renal failure with the 
use of tenofovir. Two important caveats to this literature must be 
acknowledged. First, there is no way to differentiate the cases in 
which renal failure is caused by tenofovir (attributable risk) from 
those that are related to other factors in someone on tenofovir 
(baseline risk) in these reports. Second, this trial demonstrates 
a therapeutic benefit to an important outcome among patients 
with higher viral loads.
Lynda Szczech 
SAP inhibits kidney fibrosis after unilateral ureteral obstruction (UUO). 
Photomicrograph of Sirius red stain or GFP immunofluorescence of day 14 
UUO kidneys. Abbreviations: GFP, green fluorescent protein; HSA, human 
serum albumin; hSAP, human serum amyloid P.
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